Metropolis Healthcare Limited (METROPOLIS)

About

Metropolis provides diagnostic and lab services across India. Market cap ₹11,308 Cr with stable 24–25% operating margins. Established player in India's diagnostic services, positioned in growing sector for healthcare infrastructure.

Face value: ₹2

Market cap

₹11,151 Cr

P/E

55.3×

P/B

7.4×

Dividend yield

0.9%

ROE

13.4%

ROCE

17.3%

Debt / equity

0.01

OPM

24.4%

EPS (TTM)

₹9.7

Book value

₹73.0

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

PE 56.08 prices in significant earnings growth; verify profit trajectory supports valuation
Operating margins (23.37%–25.68%) show variability; determine driver (pricing pressure, competitive intensity, mix) and sustainability
Diagnostic sector faces regulatory risk on pricing controls and referral practices; monitor government policy changes
Verify revenue concentration by customer type, service line, geography to assess dependency and contract risk

Generated analysis · source review pending

Growth drivers

Operating margins sustained 24–25% over recent quarters demonstrate operational efficiency and cash generation for reinvestment
D/E 0.01 provides significant headroom for acquisition-driven growth or organic expansion without leverage constraint
Consolidated revenue exceeds standalone (Jun 2026: ₹450.22 Cr vs ₹372.28 Cr), indicating active acquisition integration strategy

Generated analysis · source review pending

1,839 historical price candles were omitted because the exchange source has not been verified.

₹537.9-4.3%1Y

Quick read

rule-based

Pros

+Healthy operating margin of 24.4%
+Almost debt-free (debt/equity 0)
+Comfortable interest coverage of 11.9×
+Dividend payout of 51.4% of profit

Cons

No red flags triggered.

Research score

Structured signal from quality, growth, valuation and momentum.

49/100

Business quality: 63
Growth: 61
Valuation: 22

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Part ofNIFTY MICROCAP 250 NIFTY TOTAL MARKET

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Dr. Lal Path Labs Ltd.LALPATHLABLALPATHLAB	₹33,605 Cr	₹33,605 Cr	₹2,891 Cr	₹838 Cr	28.3%	₹542 Cr	18.5%	28.8%	21.6%	-79
Vijaya Diagnostic Centre LimitedVIJAYAVIJAYA	₹14,694 Cr	₹14,694 Cr	₹857 Cr	₹362 Cr	41.4%	₹187 Cr	21.3%	21.3%	19.7%	-117
Metropolis Healthcare LimitedMETROPOLISMETROPOLIS	₹11,151 Cr	₹11,169 Cr	₹1,710 Cr	₹422 Cr	24.4%	₹202 Cr	11.6%	17.3%	13.4%	-57
Thyrocare Technologies LimitedTHYROCARETHYROCARE	₹8,495 Cr	₹8,495 Cr	₹876 Cr	₹282 Cr	31.6%	₹176 Cr	19.6%	36.5%	28.8%	4
Nephrocare Health Services LimitedNEPHROPLUSNEPHROPLUS	₹6,509 Cr	₹6,589 Cr	₹999 Cr	₹227 Cr	22.7%	₹77 Cr	7.7%	17.1%	9.1%	-61
Suraksha Diagnostic LimitedSURAKSHASURAKSHA	₹1,824 Cr	₹1,826 Cr	₹325 Cr	₹102 Cr	30.7%	₹36 Cr	10.1%	16.8%	14.1%	-101
Krsnaa Diagnostics LimitedKRSNAAKRSNAA	₹1,798 Cr	₹2,332 Cr	₹815 Cr	₹218 Cr	27.4%	₹97 Cr	13.1%	13.1%	10.9%	65
3b Blackbio Dx Limited3BBLACKBIO3BBLACKBIO	₹1,416 Cr	₹1,417 Cr	₹96 Cr	₹50 Cr	52%	₹163 Cr	49.4%	25.3%	19.4%	235
One Global Service Provider LtdONEGLOBALONEGLOBAL	₹1,025 Cr	₹1,025 Cr	₹6 Cr	₹1 Cr	22.2%	₹1 Cr	17.3%	17.6%	19.5%	—
Health X Platform LimitedHEALTHXHEALTHX	₹868 Cr	₹890 Cr	₹1,468 Cr	₹-67 Cr	-4%	₹-20 Cr	-0.1%	—	0.2%	—
Gaudium Ivf And Women Health LimitedGAUDIUMIVFGAUDIUMIVF	₹797 Cr	₹820 Cr	₹104 Cr	₹38 Cr	36.1%	₹24 Cr	23.4%	23.1%	16.1%	92
Aspira Pathlab & Diagnostics LtdASPIRAASPIRA	₹135 Cr	₹136 Cr	₹22 Cr	₹4 Cr	16%	₹2 Cr	9.2%	17.5%	18.1%	16

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	761	856	998	1,228	1,148	1,208	1,331	1,646
COGS	—	204	252	276	253	243	269	325
Gross profit	—	652	746	952	895	965	1,063	1,321
	561	420	460	610	607	683	760	920
	200	232	286	343	288	283	303	401
OPM %	26.3%	27.1%	28.7%	27.9%	25.1%	23.4%	22.8%	24.4%
Depreciation	20	39	46	63	89	94	109	134
Interest	1	8	8	20	27	23	19	25
	8	-16	12	34	15	9	15	17
Profit before tax	187	169	244	293	188	175	191	259
Tax	63	41	61	79	44	46	45	68
Tax %	33.8%	24.4%	25%	26.8%	23.5%	26.5%	23.8%	26.2%
	124	128	183	215	143	128	146	191
PAT margin %	16.2%	14.9%	18.4%	17.5%	12.5%	10.6%	10.9%	11.6%
EPS (₹)	24.1	25.4	36	41.9	27.9	25	28.3	9.2
EPS adjusted (₹)	6	6.3	9	10.5	7	6.2	7	9.2
	0%	31.5%	22.2%	19.1%	28.7%	16%	0%	—
Annual report	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	10	10	10	10	10	10	10	10	41
Reserves	405	409	513	696	876	978	1,086	1,321	1,472
Minority interest	14	1	2	1	2	2	3	4	11
	1	18	—	0	259	79	0	14	19
	101	115	227	296	384	432	456	519	595
Total equity & liabilities	530	553	752	1,004	1,530	1,502	1,555	1,867	2,138
	207	213	237	343	1,059	947	997	1,277	1,406
CWIP	—	—	—	—	—	0	0	0	0
Investments	102	33	14	10	16	15	55	71	337
	221	307	501	651	456	540	503	520	395
Total assets	530	553	752	1,004	1,530	1,502	1,555	1,867	2,138

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	76.2%	74.7%	77.5%	77.9%	79.9%	79.8%	80.3%
EBITDA margin %	26.3%	27.2%	28.7%	27.9%	25.1%	23.4%	22.8%	24.4%
EBIT margin %	23.7%	22.6%	24.1%	22.8%	17.3%	15.6%	14.6%	16.2%
PAT margin %	16.2%	14.9%	18.4%	17.5%	12.5%	10.6%	10.9%	11.6%
Working capital
Receivable days	66	55	45	40	39	38	41	38
Inventory days	17	44	59	68	64	58	65	51
Payable days	0	152	160	136	136	150	171	146
NWC days	83	-54	-56	-29	-33	-53	-65	-57
Leverage
Current ratio	2.45	2.34	2.98	1.3	1.14	1.28	1.18	1.4
Debt to EBITDA	0.09	—	0	0.75	0.27	0	0.05	0.05
Debt to equity	0.04	—	0	0.29	0.08	0	0.01	0.01
Interest coverage	355.7	24.2	32.4	15.1	8	8.8	11.3	11.9
Asset turnover	1.38	1.14	0.99	0.8	0.76	0.78	0.71	0.77
Return ratios
Return on assets %	22.4%	17%	18.3%	14%	9.5%	8.3%	7.8%	8.9%
Return on capital employed %	44%	40%	36.5%	29.3%	17.4%	15.5%	14.5%	17.3%
Return on equity %	29.5%	24.4%	25.9%	24.2%	14.5%	11.7%	10.9%	12.6%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	49.74%	49.74%	49.67%	49.62%	49.43%	49.4%	48.9%	48.89%	48.89%	48.88%	48.87%	48.86%
	24.29%	21.66%	18.9%	18.25%	18.56%	16.73%	15.29%	12.83%	12.52%	11.69%	10.43%	11.03%
	16.86%	20.73%	24.86%	27.43%	28.02%	30%	30.3%	32.4%	33.1%	34.73%	35.79%	35.12%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	9.11%	7.87%	6.57%	4.7%	3.99%	3.87%	5.51%	5.88%	5.49%	4.7%	4.91%	4.99%
No. of shareholders	—	—	—	—	—	—	—	—	47,846	46,670	49,175	50,636

Promoter holding down 0.88 percentage points since Sep 2023.

42 deals · 16 Nov 2021 – 11 Aug 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
11 Aug 2026	METZ ADVISORY LLP	Block	NSE	Sell	10,50,000	₹564.00	₹59.22 Cr
11 Aug 2026	DURU SHAH FAMILY TRUST	Block	NSE	Sell	10,50,000	₹564.00	₹59.22 Cr
11 Aug 2026	METZ ADVISORY LLP	Bulk	NSE	Sell	10,50,000	₹564.00	₹59.22 Cr
11 Aug 2026	DURU SHAH FAMILY TRUST	Bulk	NSE	Sell	10,50,000	₹564.00	₹59.22 Cr
11 Aug 2026	ADITYA BIRLA SUN LIFE MUTUAL FUND	Block	NSE	Buy	10,49,000	₹564.00	₹59.16 Cr
11 Aug 2026	ADITYA BIRLA SUN LIFE MUTUAL FUND	Bulk	NSE	Buy	10,49,000	₹564.00	₹59.16 Cr
11 Aug 2026	ICICI PRUDENTIAL MUTUAL FUND	Block	NSE	Buy	5,25,500	₹564.00	₹29.64 Cr
11 Aug 2026	MORGAN STANLEY ASIA SINGAPORE PTE	Block	NSE	Buy	5,25,500	₹564.00	₹29.64 Cr
4 Dec 2025	CORE DIAGNOSTICS (MAURITIUS) PRIVATE LIMITED	Bulk	BSE	Sell	2,92,457	₹1,905.11	₹55.72 Cr
16 Oct 2025	GOLDMAN SACHS (SINGAPORE) PTE.- ODI	Block	NSE	Sell	55,000	₹1,944.00	₹10.69 Cr

1–10 of 42

1 / 5

Mrs. Ameera ShahExecutive Director-Chairperson related to Promoter
Mr. Sushil Kanubhai ShahNon-Executive - Non Independent Director
Mr. Surendran ChemmenkotilExecutive Director-MD
Mr. Hemant SachdevNon-Executive - Non Independent Director
Mrs. Aparna Chetan RajadhyakshaNon-Executive - Non Independent Director
Mr. Sanjay BhatnagarNon-Executive - Independent Director
Mr. Vivek GambhirNon-Executive - Independent Director
Mr. Subramanian RanganathanNon-Executive - Independent Director
Mrs. Purvi ShethNon-Executive - Independent Director
Mr. Rehan KhanNon-Executive - Independent Director
Mr. Sameer PatelChief Financial Officer

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

31

across 11 fund houses

Held by these funds

13.34%

of the company's equity

All mutual funds

32.67%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

31 schemes · 11 fund houses

		Shares
Portfolio of Kotak Small Cap Fund	Kotak Mahindra Mutual Fund	63.8 L	371.53	1.89%	3.078%	-0
Franklin India Small Cap Fund (Formerly known as Franklin India Smaller Companies Fund) ^	Franklin Templeton Mutual Fund	46.78 L	272.45	1.85%	2.257%	+3.05 L
SMALL CAP FUND	Nippon India Mutual Fund	45.81 L	266.79	0.32%	2.21%	-0
Healthcare FundNEW	ICICI Prudential Mutual Fund	20.92 L	121.82	1.74%	1.009%	—
BUSINESS CYCLE FUND	Tata Mutual Fund	20.42 L	118.94	4.57%	0.985%	-0
MULTICAP FUND	Tata Mutual Fund	10.96 L	63.82	1.78%	0.529%	-0
Portfolio of Kotak Contra Fund	Kotak Mahindra Mutual Fund	10.52 L	61.29	1.11%	0.508%	-0
BALANCED ADVANTAGE FUNDNEW	Tata Mutual Fund	6.65 L	38.75	0.45%	0.321%	—

1–8 of 31

1 / 4

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

30

Annual reports

8

Investor Presentation and earnings call

5

Aug 2026Transcript AI Summary PPT REC
May 2026Transcript AI Summary PPT

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

7

Interim dividend19 May 2026 · ex-date₹1
Interim dividend11 Nov 2025 · ex-date₹4
Interim dividend17 Nov 2023 · ex-date₹4
Interim dividend23 Feb 2023 · ex-date₹8
Interim dividend21 Feb 2022 · ex-date₹8
Interim dividend17 Feb 2021 · ex-date₹8
Interim dividend13 Feb 2020 · ex-date₹8

1

Board meeting to consider results4 Aug 2026

1

Bonus 3:120 Mar 2026 · ex-date

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

118 announcementsExport CSV

28 Sept 2026, 2:56 pmInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

9 Sept 2026, 6:08 pmCompany Update

Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

Allotment of ESOP / ESPS PDF

7 Sept 2026, 7:01 pmCompany Update

Announcement under Regulation 30 (LODR)-Restructuring

Restructuring PDF

7 Sept 2026, 3:33 pmInsider Trading / SAST

Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011

Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 PDF

2 Sept 2026, 6:58 pmCompany Update

Announcement under Regulation 30 (LODR)-Earnings Call Transcript

Earnings Call Transcript PDF

27 Aug 2026, 11:12 pmCompany Update

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Analyst / Investor Meet PDF

27 Aug 2026, 7:15 pmCompany Update

Disclosure Under Regulation 30 Of SEBI Listing Regulations

General PDF

27 Aug 2026, 3:39 pmCompany Update

Announcement under Regulation 30 (LODR)-Investor Presentation

Investor Presentation PDF

Date	Category	Subject	Filing
28 Sept 2026, 2:56 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
9 Sept 2026, 6:08 pm	Company Update Allotment of ESOP / ESPS	Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS	PDF

Loading announcements…

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	104	90	215	249	253	247	264	263	351
	2	35	-105	62	-735	47	-89	-201	-223
	-87	-118	-55	-33	163	-292	-181	-87	-115
Net cash flow	19	7	55	278	-319	2	-7	-25	12
Free cash flow	—	—	—	221	223	194	200	219	307
CFO / Operating profit %	—	45%	92.3%	87.1%	73.9%	85.7%	93.5%	86.7%	87.5%

Metropolis Healthcare Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Investor Presentation and earnings call

Events

7

1

1

Announcements

7

1

1

Not in the F&O segment

Announcements

Annual reports

Investor Presentation and earnings call

Compounded sales growth

Compounded profit growth

Return on equity

Metropolis Healthcare Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Investor Presentation and earnings call

Events

Dividends7

Board meetings1

Bonus issues1

Announcements

Dividends7

Board meetings1

Bonus issues1

Ratio timeline

Not in the F&O segment

Announcements

Annual reports

Investor Presentation and earnings call

Quarterly record

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

7

1

1

7

1

1